PHM

Pharmacology Day 1: Comprehensive Notes

• Perfect drug concept

  • No drug is perfect; advances bring drugs closer to ideal but trade-offs remain.

  • Ideal drug would be highly effective for the target condition (cure, prevent, or reliably manage symptoms) and be predictable in its response to a given dose.

  • In practice, many drugs are not fully predictable in the degree of response, requiring monitoring and dose adjustments.

  • Example: weight-based heparin dosing yields variable anticoagulant responses across individuals (roughly one-third under-anticoagulated, one-third at target, one-third over-anticoagulated).

  • A perfect drug would have no side effects, but that is highly unrealistic in most cases; side effects are a major driver of adherence problems.

  • Some drugs have minimal adverse effects compared with placebo, but these are rare; recognizing and managing side effects is a core nursing/pharmacology task.

  • Convenience: desire for simple regimens (e.g., once-daily dosing) to improve adherence; avoid injections/IVs when possible.

  • Accessibility and cost: cheaper, readily available drugs are preferred; newer drugs are less likely to be “perfect” by this criterion.

  • Prolonged inactive effects are undesirable; once a drug has done its job, it should be eliminated efficiently to minimize lingering issues.

  • Drug interactions: many drugs interact in ways that affect efficacy and safety; a “perfect” drug would have no problematic interactions, though real-world drugs often do.

  • In clinical practice, physicians and nurses manage imperfections across drugs: interactions, side effects, unpredictable responses, etc.

  • The course aims to identify common imperfections for drug groups and anticipate them in patient care.

• What we need to know about medications to manage them

  • Mechanism of action (MoA): how the drug produces its effect; helps predict actions and safety without rote memorization of every side effect.

  • Indications: what conditions the drug is used for; includes FDA-approved indications and off-label uses.

  • Off-label use: use outside FDA-approved indications; common but information may be less robust; prescribers exercise professional judgment.

  • Contraindications: patient conditions in which a drug should not be used due to predictable danger.

  • Adverse drug reactions (ADRs) and drug interactions: monitoring for side effects and interactions; some patients discontinue therapy due to ADRs.

  • Dosing and routes of administration: not the focus of early pharmacology content; emphasis on understanding but not memorizing extensive dosing regimens.

  • Monitoring parameters: two main sets

  • Efficacy monitoring: evidence the drug is doing what it’s supposed to do (e.g., fever/CRP improvements, infection markers like WBC with antibiotics).

  • Toxicity monitoring: labs or clinical signs indicating potential harm (e.g., liver enzymes for hepatotoxic drugs).

  • Indications vs contraindications, side effects, interactions, and monitoring form the core framework for safe drug use.

  • Drug naming and information sources (covered later) are essential to avoid errors and ensure correct use.

• Drug names and safety considerations

  • Names types

  • Chemical names: long and difficult to use in practice; generally not memorized.

  • Generic (nonproprietary) names: standardized, widely used; often provide clues about class or mechanism and are used on exams.

  • Trade (brand) names: proprietary names owned by the company; can be multiple per generic; new drugs are often discussed by brand names.

  • Examples and naming patterns

  • Generic example: acetaminophen (generic name for the active ingredient).

  • Suffix clues: many NSAIDs share the suffix -profin (e.g., ibuprofen, ketoprofen); a new NSAID ending in -profin is likely in the same class with similar actions and side effects.

  • Brand names may vary widely (e.g., Tylenol is acetaminophen) and can be regionally variable.

  • Practical exam practice

  • If slides show both generic and brand names, expect both on exams.

  • Do not memorize chemical names; they are rarely needed for exams.

  • Medication safety and errors

  • Modern systems (electronic health records, computerized order entry) reduce drug errors but do not eliminate them.

  • The two most common serious errors are: (1) wrong drug given, (2) wrong dose (too high).

  • Abbreviations can cause miscommunication; some institutions publish approved abbreviation lists; avoid ambiguous abbreviations.

  • Common pitfalls include trailing zeros (e.g., 1.0 mg vs 10 mg), naked decimals (e.g., .5 mg vs 0.5 mg), look-alike drug names, and confusing units (micrograms vs milligrams).

  • Examples of communication hazards: trailing zeros can cause tenfold dosing errors; naked decimals can be misread; spacing in drug names can prevent misreadings (e.g., Inderal risk for misreadings like Inderal a hundred forty mg).

  • How EHRs help

  • EHRs and order-entry systems provide dose checks and alerts to reduce errors, including prompts if a dose seems unusually high or low.

• Drug origins and development trends

  • Natural origins: many drugs originate from natural sources; direct plant/microbial/animal origins still exist but are less common for many modern drugs.

  • Plant sources

  • Willow bark led to aspirin via salicylate chemistry; the bark provided a historical source; now produced synthetically.

  • Animal sources

  • Insulin used to come from porcine or bovine sources; current human insulin is produced via recombinant DNA technology.

  • Premarin (pregnant mare’s urine) historically used for estrogen replacement; synthetic estrogens largely replace this origin now.

  • Microbial sources

  • Penicillin derived from Penicillium mold; many antibiotics and biologics are based on microbial products or engineered microbes.

  • Dextran (volume expander) derived from Lactobacillus.

  • Minerals

  • Some minerals (iron, magnesium, selenium) have therapeutic roles, but minerals are less common as primary drug sources.

  • Semisynthetic and synthetic evolution

  • Semisynthetic: starting from a natural product and modifying the molecule to improve properties (e.g., penicillin to ampicillin).

  • Synthetic drugs: fully chemically created; some drugs lack natural counterparts (e.g., antihistamines, many anesthetics like fentanyl).

  • Biosynthetic and biotechnologic advances

  • Biosynthetic: using engineered organisms (often bacteria) to produce complex human proteins (e.g., insulin production in bacteria after transferring the human gene).

  • Future directions include using larger organisms or cell cultures to produce complex biologics.

  • Implications

  • Drug discovery increasingly blends natural product starting points with modern chemistry and biotechnology.

• How drug information is created and accessed

  • Three main sources of drug information

  • Primary sources: original research studies and clinical trial reports published in journals.

  • Secondary sources: databases that index and categorize primary literature (e.g., PubMed, EBSCO); useful for locating studies but still requires reading primary articles to interpret results.

  • Tertiary sources: user-friendly summaries and guidelines derived from primary/secondary literature (e.g., textbooks, UpToDate, clinical guidelines, DailyMed, Orange Book).

  • How information flows in practice

  • Clinicians often start with tertiary sources for quick guidance, then consult secondary sources to locate primary studies, and finally read primary literature for detailed understanding.

  • Examples of tertiary/secondary/primary resources

  • Primary: journals (Nature, Science, specialty journals in cardiology, infectious diseases, nutrition, etc.).

  • Secondary databases: EBSCOhost (UT Library), PubMed abstracts.

  • Tertiary references: textbooks, review articles, guidelines (e.g., current hypertension guidelines endorsed by ACC/AHA).

  • Clinical guidelines and pay-for-performance

  • Guidelines compile evidence from multiple studies to provide standardized treatment approaches.

  • Growing emphasis on following guidelines to support quality care and reimbursement decisions.

  • Drug labels, official compendia, and regulatory sources

  • Drug label (FDA-approved labeling) is the authoritative source for approved uses, dosing ranges, boxed warnings, contraindications, and safety data.

  • DailyMed provides FDA drug label information; Orange Book lists FDA-approved generic equivalents.

  • USP (United States Pharmacopeia) certification signals quality and standardized manufacturing practices; USP certification is not a guarantee but a quality standard.

  • NDA and the approval process

  • Investigational New Drug (IND) application to begin human testing after animal studies show promise.

  • Phase I: safety, tolerability, pharmacokinetics in healthy volunteers.

  • Phase II: efficacy and dose-ranging studies in patients with the target condition.

  • Phase III: large, multi-site trials to establish efficacy and monitor for rare adverse effects.

  • NDA (New Drug Application): submission to FDA with all trial data; FDA reviews and decides to approve or deny.

  • From discovery to market and generics

  • Of thousands of compounds screened, only a tiny fraction reach Phase I and even fewer gain approval.

  • Brand-name drugs enjoy market exclusivity after NDA approval; generics arise after patent and exclusivity periods end.

  • Abbreviated NDA (ANDA) pathway allows generic entry using bioequivalence data rather than full clinical trials.

• Generics, bioequivalence, and market dynamics

  • Generics and cost reduction

  • Generics reduce drug costs after market exclusivity, contributing to substantial savings for patients and healthcare systems.

  • What makes a generic acceptable

  • Pharmaceutical equivalence: same active ingredient(s), same dosage form, same route of administration, and same strength.

  • Bioequivalence: similar rate and extent of absorption compared to the pioneer drug, not significantly different across key parameters.

  • How bioequivalence is assessed

  • Three key parameters: $AUC$ (Area Under the Curve), $C<em>{ ext{max}}$ (maximum concentration), and $T</em>{ ext{max}}$ (time to reach Cmax).

  • Not significantly different means the generic’s pharmacokinetic profile is close enough to the brand-name profile.

  • FDA acceptance ranges (typical BE window):

    • $0.80 \le \frac{AUC<em>{ ext{generic}}}{AUC</em>{ ext{brand}}} \le 1.25$

    • $0.80 \le \frac{C<em>{ ext{max,generic}}}{C</em>{ ext{max,brand}}} \le 1.25$

    • In practice, many discussions reference a ±20-25% window depending on the parameter.

  • Economic and rationales behind generics

  • Generics must prove bioequivalence without repeating full phase trials, enabling lower generic costs while maintaining safety and efficacy.

  • Brand-name manufacturers may collaborate or compete with generics; substitution policies vary by jurisdiction and hospital/pharmacy policy.

  • Substitution and policy

  • Some jurisdictions (e.g., Texas) have lists of drugs that cannot be substituted due to concerns about equivalent safety/efficacy, though historically no drug has been definitively shown non-equivalent to be on those lists.

  • Pharmacists often practice substitution using guidance from the Orange Book (FDA) and clinical guidelines; state laws regulate substitution rules.

  • Real-world caveats

  • Most drugs exhibit minimal clinically meaningful differences within BE ranges for many conditions.

Here are 8 multiple-choice questions based on the pharmacology notes:

1. Which of the following is NOT typically considered a characteristic of an "ideal drug" according to the notes?
   A) Highly effective for the target condition
   B) Predictable in its response to a given dose
   C) Completely free of any side effects
   D) Always administered via injection for maximum efficacy

2. According to the notes, why is understanding a drug's "Mechanism of Action" (MoA) crucial for healthcare professionals?
   A) It helps to memorize every potential side effect.
   B) It allows for rote memorization of drug interactions.
   C) It helps predict a drug's actions and safety without extensive memorization.
   D) It is primarily used to determine the FDA-approved indications.

3. Which statement correctly differentiates between generic and trade drug names?
   A) Generic names are proprietary names, while trade names are standardized.
   B) Trade names are often used on exams, while generic names are rarely needed.
   C) Generic names are standardized and often provide class clues, while trade names are proprietary and can vary.
   D) Chemical names are widely used in practice, unlike generic or trade names.

4. Insulin, initially sourced from porcine or bovine animals, is now primarily produced via:
   A) Direct extraction from specific plant species.
   B) Recombinant DNA technology using engineered organisms.
   C) Mining and purification from therapeutic minerals.
   D) Full chemical synthesis without any biological input.

5. A nursing student is looking for comprehensive, user-friendly summaries and clinical guidelines for treating hypertension. Which type of drug information source would be most appropriate for their initial search?
   A) Primary sources, such as individual clinical trial reports in research journals.
   B) Secondary sources, like PubMed for indexing individual studies.
   C) Tertiary sources, such as textbooks or UpToDate.
   D) Original Investigational New Drug (IND) applications.

6. In the FDA drug approval process, what is the primary objective of Phase I clinical trials?
   A) To establish efficacy and monitor for rare adverse effects in a large patient population.
   B) To determine safety, tolerability, and pharmacokinetics in healthy volunteers.
   C) To conduct dose-ranging studies in patients with the target condition.
   D) To submit a New Drug Application (NDA) to the FDA.

7. When assessing the bioequivalence of a generic drug compared to a brand-name drug, which of the following pharmacokinetic parameters are typically measured?
   A) Only the drug's half-life ($T<em>{1/2}$) and volume of distribution ($V</em>d$).
   B) $AUC$ (Area Under the Curve), $C<em>{\text{max}}$ (maximum concentration), and $T</em>{\text{max}}$ (time to reach Cmax).
   C) Only the rate of metabolism and excretion.
   D) The drug's therapeutic index and protein binding percentage.

8. The primary reason generic drugs are substantially cheaper than brand-name drugs is that:
   A) Generic manufacturers use lower quality active ingredients.
   B) They do not need to repeat the expensive and time-consuming full clinical trials (Phase I, II, III).
   C) Brand-name manufacturers intentionally inflate prices due to lack of competition.
   D) Generic drugs are less effective and therefore priced lower.